Aortic Stenosis Treatment Market size was valued at USD 6.91 billion in 2023 and is likely to reach USD 22.48 billion by 2036, expanding at around 9.5% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of aortic stenosis treatment is estimated at USD 7.44 billion.
The growth of the market can be attributed to high prevalence of aortic stenosis, globally. It is the third most common cardiac diseases, after hypertension, and coronary heart disease. It occurs, when the aortic valve marrows, which creates pressure in the ventricle. Globally, aortic stenosis is present in 2.5-3% of the population above 75 years of age. Furthermore, the increasing investment in developing new treatment methods for valvular heart diseases is also expected to boost the market growth.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
9.5% |
|
Base Year Market Size (2023) |
USD 6.91 billion |
|
Forecast Year Market Size (2036) |
USD 22.48 billion |
|
Regional Scope |
|
The global aortic stenosis treatment market is segmented by treatment into aortic valve repair, balloon valvuloplasty, and others, out of which, the balloon valvuloplasty segment is anticipated to hold a notable share in the market during the forecast period owing to its application in treating infants and children, or adults who are too weak for valve replacement. On the basis of end-use, the aortic stenosis treatment market is segmented into hospitals, diagnostic center, and others, out of which, the hospitals segment is anticipated to garner the largest revenue, during the forecast period, as surgery is the only permanent treatment for aortic stenosis. Moreover, increasing patient pool of aortic stenosis, especially among the geriatric population, is estimated to boost the growth of the segment.
Our in-depth analysis of the global market includes the following segments
|
By Diagnosis |
|
|
By Treatment |
|
|
By End-User
|
|
Regionally, the global aortic stenosis treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Asia Pacific is likely to hold largest revenue share by 2036, on the back of high cases of valve diseases in the region. Moreover, improving healthcare facilities and boosting economy, are estimated to generate a major scope for growth of the market, in the region.
North America Market Analysis
The aortic stenosis treatment market in the North America region is estimated to garner the largest share over the forecast period, owing to the efficient healthcare system, presence of major pharmaceutical companies in the region, and high investment in medical R&D activities. Moreover, increasing prevalence of aortic stenosis in developed countries, such as, the U.S. is estimated to boost the market growth. More than 5% of the population aged 85 years and above suffer from this disease in the U.S.
· May 18, 2021: Edwards Lifesciences Corporation announced the positive results of SAPIEN 3TAVR for patients with bicuspid aortic stenosis.
· December 15, 2021: Neovasc Inc. announced the completion of its first three Neovasc Reducer implants in France.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?